Skip to main content

Table 2 Sample sizes to detect a significant difference in disease or treatment-related combined morbidity/mortality. Numeric Results with Proportion Lost to Follow Up = 0.1200

From: The TEAM trial: Safety and efficacy of endovascular treatment of unruptured intracranial aneurysms in the prevention of aneurysmal hemorrhages: A randomized comparison with indefinite deferral of treatment in 2002 patients followed for 10 years

      

Hazard Two-sided

 

Power

N

N1

N2

S1

S2

Ratio

Alpha

Beta

0.8007

1332

666

666

0.9000

0.9500

0.4868

0.0167

0.1993

0.8006

872

436

436

0.9000

0.9600

0.3875

0.0167

0.1994

0.8006

602

301

301

0.9000

0.9700

0.2891

0.0167

0.1994

0.8004

1947

974

973

0.9100

0.9500

0.5439

0.0167

0.1996

0.8002

1168

584

584

0.9100

0.9600

0.4328

0.0167

0.1998

0.8007

757

379

378

0.9100

0.9700

0.3230

0.0167

0.1993

0.8002

3223

1612

1611

0.9200

0.9500

0.6152

0.0167

0.1998

0.8002

1688

844

844

0.9200

0.9600

0.4896

0.0167

0.1998

0.8003

1001

501

500

0.9200

0.9700

0.3653

0.0167

0.1997

0.8000

6717

3359

3358

0.9300

0.9500

0.7068

0.0167

0.2000

0.8002

2758

1379

1379

0.9300

0.9600

0.5625

0.0167

0.1998

0.8004

1424

712

712

0.9300

0.9700

0.4197

0.0167

0.1996

  1. Summary Statements: A two-sided log rank test with an overall sample size of 1688 subjects (of which 844 are in group 1 and 844 are in group 2) achieves 80% power at a 0.0167 significance level to detect a difference of 0.0400 between 0.9200 and 0.9600 – the proportions surviving in groups 1 and 2, respectively. This corresponds to a hazard ratio of 0.4896. The proportion of patients lost during follow up was 0.1200.